Neurosterix completes Phase 1 studies of NTX-253 for schizophrenia
Addex Therapeutics’ spin-out Neurosterix has completed Phase 1 clinical studies of NTX-253 for schizophrenia.
Addex Therapeutics’ spin-out Neurosterix has completed Phase 1 clinical studies of NTX-253 for schizophrenia.